



**LINCOLN**  
PHARMACEUTICALS LTD.  
HEALTHCARE FOR ALL

Date: August 14, 2018

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited</b> , Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051. <b>Scrip Code - LINCOLN</b>	To, The Department of Corporate Service, <b>BSE Limited, (BSE)</b> Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001. <b>Scrip Code - 531633</b>
--	--

Dear Sir,

**SUB.: OUTCOME OF BOARD MEETING.**

With reference to the above, we would like to inform that the Board of Directors of the Company at their meeting held today, i.e. on Tuesday, August 14, 2018, had approved the following;

1. To Considered and Approved Standalone and Consolidated Un-Audited Financial Results for the Quarter Ended on June 30, 2018.
2. The Limited Review Report on Standalone and Consolidated Un-Audited Financial Results received from Statutory Auditors for the aforesaid Quarter.
3. The Financial Performance Highlights for the Quarter Ended on June 30, 2018.

The meeting of the Board of Directors of the Company commenced at 10.30 a.m. and concluded at 12.15 p.m.

We request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

**FOR LINCOLN PHARMACEUTICALS LIMITED**



(AUTHORISED SIGNATORY)

Encl: As above

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India  
Phone : +91-79-6777 8000 | Fax : +91-79-6777 8062 | CIN L24230GJ1995PLC024288  
E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721. Ta. : Kalol, Dist. Gandhinagar, (Guj.)  
Phone : 02764-665000 | Fax : 02764-281809  
E-mail : khatraj@lincolnpharma.com





# LINCOLN PHARMACEUTICALS LIMITED



Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad -380060.

CIN: L24230G1995PLC024288, Ph. No.: +91-79-67778000, Fax: +91-79-6777 8062,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com

LINCOLN  
PHARMACEUTICALS LTD.  
HEALTHCARE FOR ALL

LINCOLN  
PHARMACEUTICALS LTD.  
HEALTHCARE FOR ALL

## Statement of Standalone and Consolidated Un-Audited Financial Results for the Quarter Ended on 30-June-2018.

Part-I Sr. No.	Particulars	Standalone				Consolidated				(Rs. in Lakhs)
		Quarter Ended		Year Ended		Quarter Ended		Year Ended		
		30/06/2018 Un-Audited	31/03/2018 Un-Audited	30/06/2017 Un-Audited	31/03/2018 Audited	30/06/2018 Un-Audited	31/03/2018 Un-Audited	30/06/2017 Un-Audited	31/03/2018 Audited	
1	<b>Income</b>									
	A) Revenue From Operations	9,663.16	7,249.54	8,775.21	32,551.19	9,982.16	6,712.46	15,023.20	36,163.71	
	B) Other Income	224.03	167.37	255.74	580.38	229.65	85.67	284.24	545.37	
	<b>Total Income</b>	<b>9,887.19</b>	<b>7,416.91</b>	<b>9,030.95</b>	<b>33,131.57</b>	<b>10,211.81</b>	<b>6,798.13</b>	<b>15,307.44</b>	<b>36,709.08</b>	
2	<b>Expenses</b>									
	A) Cost of Material Consumed	1,816.31	1,662.08	1,255.03	6,359.23	2,654.94	2,470.54	1,810.51	9,155.30	
	B) Purchase of Stock-In-Trade	2,240.91	2,185.41	4,245.88	10,686.23	1,090.91	688.10	9,668.25	10,393.98	
	C) Changes in Inventories of Finished Goods, Stock-In-Trade and WIP	420.91	(458.63)	208.92	70.65	723.29	(656.50)	145.07	(297.61)	
	D) Excise Expenses	Nil	Nil	55.76	55.76	Nil	(21.09)	67.61	102.28	
	E) Employee Benefits Expenses	1,269.04	1,011.80	1,050.22	4,750.80	1,352.03	1,146.31	1,117.37	5,114.78	
	F) Finance Costs	81.87	111.28	117.43	426.47	133.26	93.95	160.79	541.10	
	G) Depreciation and Amortisation Expense	13.82	110.41	96.00	439.93	158.02	153.06	138.00	611.18	
	H) Other Expenses	1,749.39	2,013.29	1,377.19	6,032.69	1,831.64	2,120.15	1,512.89	6,463.36	
	<b>Total Expenses</b>	<b>7,692.24</b>	<b>6,635.64</b>	<b>8,406.43</b>	<b>28,821.77</b>	<b>7,944.09</b>	<b>5,994.52</b>	<b>14,620.49</b>	<b>32,084.37</b>	
3	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>2,194.96</b>	<b>781.27</b>	<b>624.52</b>	<b>4,309.80</b>	<b>2,267.72</b>	<b>803.61</b>	<b>686.95</b>	<b>4,624.71</b>	
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
5	<b>Profit / (Loss) after Exceptional Items but Before Tax (3-4)</b>	<b>2,194.96</b>	<b>781.27</b>	<b>624.52</b>	<b>4,309.80</b>	<b>2,267.72</b>	<b>803.61</b>	<b>686.95</b>	<b>4,624.71</b>	
6	Tax Expense									
	A. Current Tax (Net)	579.63	59.95	126.17	958.49	596.29	75.83	140.15	1,038.47	
	B. Deferred Tax (Net)	55.00	2.62	48.00	75.66	64.00	45.16	55.11	121.30	
7	<b>Profit / Loss For The Period (5-6)</b>	<b>1,560.33</b>	<b>718.70</b>	<b>450.35</b>	<b>3,275.65</b>	<b>1,607.43</b>	<b>682.62</b>	<b>491.69</b>	<b>3,464.94</b>	
8	Attributable to:									
	Non-Controlling Interest	Nil	Nil	Nil	Nil	0.64	(0.34)	0.65	2.79	
	<b>Owners of the Company</b>	<b>1,560.33</b>	<b>718.70</b>	<b>450.35</b>	<b>3,275.65</b>	<b>1,606.79</b>	<b>682.96</b>	<b>491.04</b>	<b>3,462.15</b>	
9	Other Comprehensive Income (Net Of Tax)	2.29	13.86	(1.55)	9.20	2.46	14.35	(1.49)	9.87	
10	<b>Total Comprehensive Income For The Period (11+12)</b>	<b>1,562.62</b>	<b>732.56</b>	<b>448.80</b>	<b>3,284.85</b>	<b>1,609.25</b>	<b>697.31</b>	<b>489.55</b>	<b>3,472.02</b>	
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	
12	Other Equity				19,954.03				20,454.44	
13	Earnings Per Share (of Rs. 10/- Each) (Not Annualised)									
	(A) Basic	7.80	3.59	2.25	16.38	8.03	3.41	2.46	17.31	
	(B) Diluted	7.80	3.59	2.25	16.38	8.03	3.41	2.46	17.31	



Notes:	
1	The Above Results have been Reviewed By the Audit Committee and Approved By The Board of Directors at their Meeting Held on August 14, 2018.
2	Statutory Auditors have carried out Limited Review of the Financial Results for the Quarter Ended June 30, 2018.
3	The Figures for the Quarter Ended March 31, 2018 are balancing Figures between Audited Figures In Respect of Full Financial Year and Un-Audited Published Figures Up to The Third Quarter.
4	The company is primarily engaged in one business segment namely Pharmaceuticals segment as determined by the chief operating decision maker in accordance with IND-AS-108, "Operating Segment".
5	Previous periods figures have been regrouped and rearranged wherever necessary.
6	Consolidated Financial Results Includes the Results of Its Subsidiaries.

FOR LINCOLN PHARMACEUTICALS LIMITED



*Mahendra G. Patel*

MAHENDRA G. PATEL  
MANAGING DIRECTOR  
DIN: 00104706

PLACE: AHMEDABAD  
DATE: AUGUST 14, 2018